x
Filter:
Filters applied
- Reviews
Publication Date
Please choose a date range between 2006 and 2022.
Author
- Gasbarrini, Antonio7
- Armuzzi, Alessandro6
- Capurso, Gabriele6
- Marzioni, Marco6
- Savarino, Edoardo6
- Alpini, Gianfranco5
- Alvaro, Domenico5
- Bouché, Olivier5
- Danese, Silvio5
- Peyrin-Biroulet, Laurent5
- Andreone, Pietro4
- Bruno, Raffaele4
- Burra, Patrizia4
- Conte, Dario4
- Invernizzi, Pietro4
- Savarino, Vincenzo4
- Andreone, P3
- Angelico, Francesco3
- Bianchi Porro, G3
- Aghemo, Alessio2
- Alisi, Anna2
- Alvaro, D2
- Annese, Vito2
- Brunetto, M2
- Bruno, Savino2
Keyword
- Crohn's disease22
- Cirrhosis17
- Ulcerative colitis17
- Inflammatory bowel disease16
- Colorectal cancer13
- Liver transplantation13
- Diagnosis12
- Chemotherapy11
- Colonoscopy10
- HCC10
- IBD9
- HCV8
- Liver cirrhosis8
- GERD7
- Hepatocellular carcinoma7
- Endoscopy6
- HBV6
- Portal hypertension6
- Surgery6
- Dysplasia5
- ERCP5
- Immunosuppression5
- Pancreatic cancer5
- Treatment5
- Alcoholic liver disease4
Reviews
305 Results
- Review ArticleOpen Access
Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review
Digestive and Liver DiseaseVol. 53Issue 7p803–808Published online: March 17, 2021- Alessandro Armuzzi
- Giuseppina Liguori
Cited in Scopus: 20As a chronic inflammatory disease, ulcerative colitis has significant negative impact on the quality of life (QoL) of patients. Since the disease affects many aspects of QoL, comprising multiple domains, treatments that induce and maintain remission can provide benefits beyond hard clinical endpoints. Effective treatment of ulcerative colitis can restore QoL and return it to normal or near normal levels. Biological therapies have shown consistent improvement in the QoL of patients with ulcerative colitis during the induction phase, with benefits that are generally maintained in the long-term. - Review Article
Histopathology of non-IBD colitis practical recommendations from pathologists of IG-IBD Group
Digestive and Liver DiseaseVol. 53Issue 8p950–957Published online: March 9, 2021- Luca Reggiani Bonetti
- Giuseppe Leoncini
- Marco Daperno
- Maria Beatrice Principi
- Carla Baronchelli
- Stefania Manenti
- and others
Cited in Scopus: 1Pathologists are often called upon to diagnose colitides that differ from the two main forms of inflammatory bowel disease (IBD). These non-IBD colitides include infectious colitis, microscopic colitis, ischemic colitis, eosinophilic colitis, autoimmune enterocolitis, segmental colitis associated with diverticulosis, drug-induced colitis, radiation colitis and diversion colitis. The diagnosis of these different disease entities relies on the histopathological examination of endoscopic biopsies of the gastrointestinal tract. - Review Article
Gastrointestinal endoscopy in children and adults: How do they differ?
Digestive and Liver DiseaseVol. 53Issue 6p697–705Published online: March 7, 2021- Sara Isoldi
- Salvatore Cucchiara
- Alessandro Repici
- Diana G. Lerner
- Mike Thomson
- Salvatore Oliva
Cited in Scopus: 3Gastrointestinal endoscopy has grown dramatically over the past century, and with subsequent improvements in technology and anaesthesia, it has become a safe and useful tool for evaluation of GI pathology in children. There are substantial differences between paediatric and adult endoscopy beyond size, including: age-related patho-physiology and the different spectrum of diseases in children. Literature on endoscopic procedures in children is sparse but significant. The present review aims at describing the current knowledges on paediatric endoscopy practice and highlights the main areas of differences between paediatric and adult practice. - Review Article
Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know
Digestive and Liver DiseaseVol. 53Issue 6p691–696Published online: February 6, 2021- Lucas Guillo
- Ferdinando D'Amico
- Hamza Achit
- Carole Ayav
- Francis Guillemin
- Silvio Danese
- and others
Cited in Scopus: 5The kidney function monitoring is recommended in routine practice to detect 5-aminosalicylic acid (5-ASA) related nephrotoxicity, although is not standardized. The optimal monitoring is unknown, especially the best timing and which tests to perform. We summarized why, how, and when to perform the monitoring for patients treated with 5-ASA and provided an overview of the current guidelines on this topic. - Review Article
Inflammatory bowel diseases and the risk of adverse health outcomes: Umbrella review of meta-analyses of observational studies
Digestive and Liver DiseaseVol. 53Issue 7p809–816Published online: February 4, 2021- Xiaoding Shen
- Qianyi Wan
- Rui Zhao
- Yutao Wu
- Yong Wang
- Yaping Cui
- and others
Cited in Scopus: 8Accumulating evidence indicates a plausible association between inflammatory bowel diseases and the risk of adverse health outcomes. However, the conclusions are inconsistent. We aimed to perform an umbrella review of meta-analyses to appraise and grade the evidence of the association between inflammatory bowel diseases and the risk of adverse health outcomes. - Review Article
From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies
Digestive and Liver DiseaseVol. 53Issue 5p558–565Published online: February 1, 2021- Massimo Claudio Fantini
- Ilaria Guadagni
Cited in Scopus: 34The risk of colorectal cancer (CRC) is higher in patients with inflammatory bowel disease (IBD). Population-based data from patients with ulcerative colitis (UC) estimate that the risk of CRC is approximately 2- to 3-fold that of the general population; patients with Crohn's disease appear to have a similar increased risk. However, the true extent of colitis-associated cancer (CAC) in undertreated IBD is unclear. Data suggest that the size (i.e., severity and extent) and persistence of the inflammatory process is largely responsible for the development of CRC in IBD. - Review Article
Systematic assessment of environmental factors for gastroesophageal reflux disease: An umbrella review of systematic reviews and meta-analyses
Digestive and Liver DiseaseVol. 53Issue 5p566–573Published online: December 15, 2020- Yuan Cheng
- Fushun Kou
- Jiali Liu
- Yi Dai
- Xiaohong Li
- Junxiang Li
Cited in Scopus: 4Side effects of long-term acid suppression have increased the scholars’ interest in nonpharmacologic intervention. - Review Article
IBDs and the pediatric age: Their peculiarities and the involvement of the microbiota
Digestive and Liver DiseaseVol. 53Issue 1p17–25Published online: November 11, 2020- Lucia Cococcioni
- Simona Panelli
- Ilaria Varotto-Boccazzi
- Domenico Di Carlo
- Dario Pistone
- Gabriella Leccese
- and others
Cited in Scopus: 4Inflammatory Bowel Diseases (IBDs) are gastrointestinal disorders characterized by chronic, relapsing inflammation, with growing incidence worldwide over the last decades and distinctive features in the pediatric age. An increasing body of evidence indicates that gut microbiota plays a major role in inflammatory disorders, including IBDs. In this review we will discuss the most recent evidences on dysbiotic changes associated with gut inflammation, as well as environmental and genetic factors contributing to IBD pathogenesis, with a focus on the peculiarities of the pediatric age. - Review Article
Current status of systemic therapy in hepatocellular cancer
Digestive and Liver DiseaseVol. 53Issue 4p397–402Published online: October 21, 2020- Shahid Ahmed
- Lexis Gordon
- Dorie-Anna Dueck
- Osama Souied
- Kamal Haider
Cited in Scopus: 2Hepatocellular cancer (HCC) is a common cancer and an important cause of cancer-related death globally. Although surgery is the primary curative treatment, most patients at diagnosis are not surgical candidates and are treated with liver-directed therapy and or systemic therapy. Over the past decade, the systemic treatment options for patients with advanced HCC have evolved. This paper reviews recent progress in systemic therapy and the results of major clinical trials involving novel compounds in patients with HCC. - Review Article
Medical therapy versus surgery in moderate-to-severe ulcerative colitis
Digestive and Liver DiseaseVol. 53Issue 4p403–408Published online: October 10, 2020- Gionata Fiorino
- Silvio Danese
- Giovanni Giacobazzi
- Antonino Spinelli
Cited in Scopus: 4Ulcerative colitis, a chronic inflammatory condition that affects the colon from rectum to caecum, is characterized by periods of increased bowel movements, blood in feces, rectal urgency, tenesmus, and abdominal pain, with periods of remission and flares of disease, which negatively impact quality of life. A number of therapeutic options are available for patients with moderate-to-severe ulcerative colitis, however, no clear treatment algorithm exists. Therapeutic goals include short-term benefits for patients (i.e., the reduction/absence of symptoms, essentially stool frequency and rectal bleeding) and long-term benefits (i.e., sustained clinical remission, steroid-free remission, and mucosal healing). - Review Article
Update on gastroenteropancreatic neuroendocrine tumors
Digestive and Liver DiseaseVol. 53Issue 2p171–182Published online: September 7, 2020- Valentina Andreasi
- Stefano Partelli
- Francesca Muffatti
- Marco F. Manzoni
- Gabriele Capurso
- Massimo Falconi
Cited in Scopus: 18The incidence gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) has dramatically risen over the last three decades, probably due to the increased detection of asymptomatic lesions. The diagnostic work-up for patients with suspected GEP-NENs is based on conventional imaging, endoscopy, pathology, and functional imaging, including 68Gallium-DOTATATE PET and 18F-FDG PET. The choice of the best treatment strategy should be based on the evaluation of tumor-related features and patient's characteristics. - Review Article
Regenerative hepatology: In the quest for a modern prometheus?
Digestive and Liver DiseaseVol. 52Issue 10p1106–1114Published online: August 29, 2020- Margarita Papatheodoridi
- Giuseppe Mazza
- Massimo Pinzani
Cited in Scopus: 2As liver-related morbidity and mortality is rising worldwide and orthotopic liver transplantation (OLT) remains the only standard-of-care for end-stage liver disease or acute liver failure, shortage of donor organs is becoming more prominent. Importantly, advances in regenerative Hepatology and liver bioengineering are bringing new hope to the possibility of restoring impaired hepatic functionality in the presence of acute or chronic liver failure. Hepatocyte transplantation and artificial liver-support systems were the first strategies used in regenerative hepatology but have presented various types of efficiency limitations restricting their widespread use. - Commentary
Addressing long-term PPI safety
Digestive and Liver DiseaseVol. 52Issue 8p853–856Published online: June 26, 2020- Carmelo Scarpignato
- Salvatore Tolone
Cited in Scopus: 3The advent of antisecretory drugs, such H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs), has revolutionized the management of acid-related diseases, leading to the virtual abolition of elective surgery for ulcer disease and relegating anti-reflux surgery to patients with reflux disease not adequately managed by medical therapy. PPIs remain the mainstay of medical treatment for gastro-esophageal reflux disease (GERD) [1–3]. They act indirectly by reducing the amount and concentration of gastric secretion available for reflux, thus lessening the aggressive power of the refluxed material [4]. - Review ArticleOpen Access
Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice
Digestive and Liver DiseaseVol. 52Issue 11p1259–1265Published online: June 26, 2020- Alessandro Armuzzi
- Yoram Bouhnik
- Fraser Cummings
- Marion Bettey
- Burkhard Pieper
- Taegyun Kang
Cited in Scopus: 6Anti-tumour necrosis factor (TNF) agents such as infliximab and adalimumab have greatly altered the treatment landscape in inflammatory bowel disease (IBD). However, there are remaining unmet needs and opportunities to optimise their use. Recent data suggest that proactive therapeutic drug monitoring may lead to more efficient usage of these agents, with potential for higher rates of corticosteroid-free clinical remission than with reactive monitoring. Expanded application of faecal calprotectin measurements may also be valuable, given the ease of use of the assay and its proven effectiveness as a diagnostic tool and predictor of relapse risk. - Review Article
Safety of probiotics in humans: A dark side revealed?
Digestive and Liver DiseaseVol. 52Issue 9p981–985Published online: June 18, 2020- Fabio Pace
- Federico Macchini
- Valeriano Massimo Castagna
Cited in Scopus: 4The term probiotic (i.e. “for life”, from the Latin and Greek words pro and bios) is relatively new, being officially introduced in 1953 by the German physician Werner Kollath [1] to designate “active substances that are essential for a healthy development of life”, though its modern definition is closer to Parker's (1974) “organisms and substances which contribute to intestinal microbial balance” [2]. In 2001 WHO/FAO proposed “live microorganisms which when administered in adequate amounts confer a health benefit on the host” [3], definition substantially left unchanged by The International Scientific Association for Probiotics and Prebiotics (ISAPP) in 2014 [4]. - Review Article
Increased risk of acute liver failure by pain killer drugs in NAFLD: Focus on nuclear receptors and their coactivators
Digestive and Liver DiseaseVol. 53Issue 1p26–34Published online: June 13, 2020- Maria Arconzo
- Elena Piccinin
- Antonio Moschetta
Cited in Scopus: 8Non-alcoholic fatty liver disease (NAFLD) is a global condition characterized by an accumulation of lipids in the hepatocytes. NAFLD ranges from simple steatosis, a reversible and relatively benign condition, to fibrosis with non-alcoholic steatohepatitis (NASH), potentially leading to cirrhosis and hepatocarcinoma. NAFLD can increase the susceptibility to severe liver injury with eventual acute liver failure induced by specific hepatotoxic drugs, including acetaminophen (APAP), which is commonly used as analgesic and antipyretic. - Review Article
What gastroenterologists should know about direct oral anticoagulants
Digestive and Liver DiseaseVol. 52Issue 10p1115–1125Published online: June 9, 2020- F. Radaelli
- L. Fuccio
- S. Paggi
- C. Del Bono
- J.M. Dumonceau
- F. Dentali
Cited in Scopus: 7Direct oral anticoagulants are being increasingly used in patients with non-valvular atrial fibrillation and venous thromboembolism, due to their improved efficacy/ safety ratio, a predictable anticoagulant effect without need for routine coagulation monitoring, and fewer food and drug interactions compared with vitamin K antagonists. Gastrointestinal bleeding remains a serious complication, whose management is challenging for gastroenterologists due to the lack of a standardized clinical approach. - Review Article
Latest insights into the hot question of proton pump inhibitor safety – a narrative review
Digestive and Liver DiseaseVol. 52Issue 8p842–852Published online: June 6, 2020- Vincenzo Savarino
- Elisa Marabotto
- Manuele Furnari
- Fabiana Zingone
- Patrizia Zentilin
- Edoardo Savarino
Cited in Scopus: 20Proton pump inhibitors (PPIs) are among the most widely prescribed medications worldwide and their use is continuously increasing. Although they have been shown to combine high therapeutic efficacy and good safety profile in many studies, in last years we have witnessed the publication of many articles reporting the possible association of long-term PPI therapy with important unexpected adverse events and these observations have created alarmism in both patients and physicians. However, the majority of these studies are observational, retrospective and prone to residual confounding. - Review Article
A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring
Digestive and Liver DiseaseVol. 52Issue 9p966–980Published online: June 5, 2020- Edoardo Savarino
- Marzio Frazzoni
- Elisa Marabotto
- Patrizia Zentilin
- Paola Iovino
- Mario Costantini
- and others
Cited in Scopus: 17Patients with esophageal symptoms potentially associated with gastroesophageal reflux disease such as heartburn, regurgitation, chest pain, or cough represent one of the most frequent reasons for referral to gastroenterological evaluation. The utility of esophageal reflux monitoring in clinical practice is: (1) to accurately define reflux burden, (2) to segregate patients according to reflux monitoring results as true GERD, reflux hypersensitivity and functional heartburn, and (3) to establish a treatment plan. - Review Article
Apnea in preterm neonates: what's the role of gastroesophageal reflux? A systematic review
Digestive and Liver DiseaseVol. 52Issue 7p723–729Published online: May 15, 2020- Paolo Quitadamo
- Valentina Giorgio
- Letizia Zenzeri
- Mariella Baldassarre
- Francesco Cresi
- Osvaldo Borrelli
- and others
Cited in Scopus: 2A causal relationship between gastro-esophageal reflux (GER) and apnea in preterm infants has been frequently hypothesized and is currently debated. The present study aims at reviewing the currently available scientific evidence, in order to clarify the role of GER on the occurrence of apnea and to help improving the clinical management of apneic preterm neonates. We performed a systematic literature search to identify all the clinical studies on preterm neonates that properly assessed the relationship between apnea and GER. - Review Article
The coeliac stomach: A review of the literature
Digestive and Liver DiseaseVol. 52Issue 6p615–624Published online: April 12, 2020- Ilaria Marsilio
- Gemma Maddalo
- Matteo Ghisa
- Edoardo Vincenzo Savarino
- Fabio Farinati
- Fabiana Zingone
Cited in Scopus: 4Beyond the small intestine, coeliac disease (CeD) may affect other gastrointestinal tracts, including the stomach. However, various studies have reported conflicting results regarding the association between CeD and gastric manifestations. The aim of this study was to analyze the existing literature on gastric involvement in CeD. A literature search was conducted in bibliographic databases of Embase, PubMed, Scopus, and Web of Science. Studies reporting the association between CeD and gastric disorders were examined in detail and are fully described in the review. - Review Article
Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist
Digestive and Liver DiseaseVol. 52Issue 4p368–373Published online: February 11, 2020- Francesca Carubbi
- Maria Domenica Cappellini
- Silvia Fargion
- Anna Ludovica Fracanzani
- Fabio Nascimbeni
Cited in Scopus: 12Gaucher disease (GD), a rare lysosomal storage disorder caused by deficient glucocerebrosidase activity and consequent accumulation of glycosphingolipids in the mononuclear phagocyte system, may progress to disabling and potentially life-threatening complications when left undiagnosed and untreated. Unfortunately, because of non-specific signs and symptoms and lack of awareness, patients with type 1 GD, the most common non-neuropathic variant, frequently experience diagnostic delays. Since splenomegaly and thrombocytopenia are the dominant clinical features in many GD patients leading to first medical contact, the hepatologist and the gastroenterologist need to be aware of this condition. - Review Article
AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement
Digestive and Liver DiseaseVol. 52Issue 4p359–367Published online: January 2, 2020- Fabio Nascimbeni
- Carlo Dionisi Vici
- Umberto Vespasiani Gentilucci
- Francesco Angelico
- Valerio Nobili
- Salvatore Petta
- and others
Cited in Scopus: 7Lysosomal storage diseases (LSDs) are a heterogeneous group of inherited disorders caused by loss-of-function mutations in genes encoding for lysosomal enzymes/proteins. The consequence is a progressive accumulation of substrates in these intracellular organelles, resulting in cellular and tissue damage. The overall incidence is about 1/8000 live births, but is likely underestimated. LSDs are chronic progressive multi-systemic disorders, generally presenting with visceromegaly, and involvement of the central nervous system, eyes, the skeleton, and the respiratory and cardiovascular systems. - Review Article
Understanding short bowel syndrome: Current status and future perspectives
Digestive and Liver DiseaseVol. 52Issue 3p253–261Published online: December 28, 2019- Sara Massironi
- Federica Cavalcoli
- Emanuele Rausa
- Pietro Invernizzi
- Marco Braga
- Maurizio Vecchi
Cited in Scopus: 51Short bowel syndrome (SBS) is a rare malabsorptive disorder as a result of the loss of bowel mass mostly secondary to surgical resection of the small intestine. Other causes are vascular diseases, neoplasms or inflammatory bowel disease. The spectrum of the disease is widely variable from single micronutrient malabsorption to complete intestinal failure, depending on the remaining length of the small intestine, the anatomical portion of intestine and the function of the remnant bowel. Over the last years, the management of affected patients has remarkably improved with the increase in patients’ quality of life and survival, mainly thanks to advances in home-based parenteral nutrition (PN). - Review Article
Pediatric liver diseases and ocular changes: What hepatologists and ophthalmologists should know and share with each other
Digestive and Liver DiseaseVol. 52Issue 1p1–8Published online: December 13, 2019- Livio Vitiello
- Maddalena De Bernardo
- Salvatore Guercio Nuzio
- Claudia Mandato
- Nicola Rosa
- Pietro Vajro
Cited in Scopus: 16Several rare pediatric liver disorders are accompanied by ophthalmic signs whose awareness and early identification may be of value in confirming/accelerating their diagnosis. Many of these signs are asymptomatic and can only be detected with an ophthalmological examination. Corneal signs are described in patients with Wilson’s disease, Alagille’s syndrome and some liver storage diseases. Cataract plays an important role to diagnose galactosemia. Retinal involvement is seen in some peroxisomal disorders (e.g.